What's Happening?
Megan Kaverman and her sister Katie Gusching have become advocates for pulmonary arterial hypertension (PAH) after both were diagnosed with the rare genetic disorder. Kaverman, diagnosed at 27, experienced symptoms like shortness of breath and fatigue
for years before receiving a diagnosis. Her sister, Gusching, noticed similar symptoms and was diagnosed two years later. PAH is a condition where mutations cause the small arteries in the lungs to narrow, increasing blood pressure and straining the heart. The sisters receive treatment at the Cleveland Clinic and participate in clinical trials to explore new care options.
Why It's Important?
The sisters' story highlights the challenges of diagnosing rare diseases and the importance of awareness and advocacy. Heritable pulmonary arterial hypertension affects fewer than one in a million people, often leading to heart failure before diagnosis. By sharing their experiences, Kaverman and Gusching aim to raise awareness and encourage others with unresolved cardiac symptoms to seek medical advice. Their advocacy efforts could lead to earlier diagnoses and better outcomes for others with similar conditions.
What's Next?
Kaverman and Gusching continue to participate in clinical trials and advocate for PAH awareness. They plan to travel and engage in activities they once thought impossible due to their condition. Their ongoing involvement in research and advocacy may contribute to advancements in treatment options and increased public awareness of PAH. The sisters' efforts could inspire others to become advocates for rare diseases, potentially leading to improved diagnosis and management strategies.
Beyond the Headlines
The sisters' journey underscores the emotional and psychological impact of living with a rare disease. Their story highlights the importance of support networks and the role of family in managing chronic conditions. It also raises questions about the accessibility of healthcare and the need for more comprehensive screening processes for rare diseases. As advocates, Kaverman and Gusching are not only raising awareness but also contributing to a broader conversation about healthcare equity and the need for personalized medicine approaches.
